What is Orasis Pharmaceuticals?
Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company that has developed QLOSI, an FDA-approved prescription eye drop designed as an alternative to reading glasses for individuals with presbyopia. The company's focus on addressing unmet needs in vision care positions it as a notable player in the pharmaceutical landscape. Its strategic financing rounds indicate a trajectory towards scaling its operations and market penetration.
How much funding has Orasis Pharmaceuticals raised?
Orasis Pharmaceuticals has raised a total of $126M across 4 funding rounds:
Series B
$13M
Series C
$30M
Debt
$15M
Series D
$68M
Series B (2018): $13M with participation from Visionary Ventures
Series C (2020): $30M led by Visionary Ventures, SBI Innovation Fund, Bluestem Capital, Steamboat Ventures, Maverick Ventures, and LifeSci Venture Partners
Debt (2024): $15M supported by Catalio Capital Management
Series D (2024): $68M featuring Johnson & Johnson Innovation and Arboretum Ventures
Key Investors in Orasis Pharmaceuticals
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a pharmaceutical manufacturing company focused on positively impacting human health through innovation. They partner with entrepreneurs and early-stage businesses to develop healthcare solutions globally, operating through regional innovation centers.
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience investing in innovative healthcare solutions. They focus on early-stage startups in under-ventured markets, aiming to improve patient outcomes and reduce healthcare costs.
Visionary Ventures
Visionary Ventures is a venture capital firm that connects capital and insight with promising life sciences and ophthalmology startups. They leverage partnerships with KOLs and industry experts to invest in companies addressing unmet medical needs.
What's next for Orasis Pharmaceuticals?
The substantial enterprise-level funding and strategic investment received by Orasis Pharmaceuticals signal a critical growth phase. This capital infusion is likely to accelerate the commercialization of QLOSI, expand its market reach, and potentially fund further research and development into other ophthalmic solutions. The company's ability to attract major investors like Johnson & Johnson Innovation and Arboretum Ventures suggests strong confidence in its technology and market strategy, paving the way for significant advancements in the treatment of vision-related conditions.
See full Orasis Pharmaceuticals company page
